When new drugs are approved, the marketing authorization holders often have to commit themselves to perform additional post-authorization studies. These studies have a different set up. Most countries have adjusted the regulations for studies where the drug is commercially available; although there is no "one fits all" concept.
THE INSIGHT SERIES: Why do prescribers participate? - Part III
While Phase II-III studies include small datasets, comprising several hundred to several thousand patients, they provide the data necessary for drug…
Our Embedded Solutions™ model helps clients execute their product portfolios more efficiently, with greater control, standardization, consistency,…
Join PRA in China
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.